Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272
Leerink Partners analyst David Risinger maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $276 to $272.
Share
Why It Matters
An expert analyst still thinks Johnson & Johnson is a good company. They slightly lowered their price guess from $276 to $272.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.